Vanda Pharmaceuticals Comments on Gastroparesis: Clinical Evaluation of Drugs for Treatment
WASHINGTON, Oct. 30 -- Vanda Pharmaceuticals has issued a public comment on the Food and Drug Administration's notice entitled "Gastroparesis: Clinical Evaluation of Drugs for Treatment; Draft Guidance for Industry; Availability". The comment was written on Oct. 15, 2019, and posted on Oct. 22, 2019:
* * *
Reference is made in the following document to the proposed Draft Guidance for Industry on Gastroparesis, published in the Federal Register August 14, 2019.